None listed
Conditions
Interventions
Randomisation of sequential versus concurrent chemoradiotherapy.
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: 1. Pathologically confirmed Non-small cell lung cancer; 2. Medically inoperable or irresectable NSCLC T 1-4, N0-3, M0; 3. Age >18 yr; 4. Weight loss 0.99l, TLCO> 59%.
Exclusion criteria
Exclusion criteria: 1. Previous chemotherapy and/or radiotherapy of the chest; 2. Superior Vena cava syndrome; 3. Hemoptysis causing a decrease of the blood haemoglobin of > 1 mmol/L within 24 hours; 4. Pleural or pericardial effusion (except if negative cytology); 5. Uncontrolled infection; 6. Maximal length of the esophagus receiving 40 Gy of more than 18 cm, or maximal length of the esophagus receiving 66 Gy of more than 12 cm; 7. Serious medical risk factors involving any of the major organ systems which may prevent adherence to the treatment schedule; 8. Patients with pre-existant fibrotic lung disease; 9. Creatinin clearance 1.25 x normal value; 10. Bone marrow hypoplasia(Hb,6.8mmol/l, WBC,4x10 9 /l, platelets,100x10 9/l; 11. Recent myocardial infarction(<6 months) or evidence of heart failure; 12. Impossibility to limit the spinal cord dose to a maximum of 50Gy; 13. Impossibility to exclude 2/3 of the heart from the boost volume.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-free survival, local control, pattern of recurrence. | — |
Secondary
| Measure | Time frame |
|---|---|
| Acute and late toxicity, Quality of Life. | — |
Contacts
Public ContactA.L.J. Uitterhoeve
Academic Medical Center (AMC), Department of Radiotherapy, P.O. Box 22660
Outcome results
None listed